Showing 3921-3930 of 5646 results for "".
- Visiox Pharma Licenses Glaucoma Drug Omlonti from Santenhttps://modernod.com/news/visiox-pharma-licenses-glaucoma-drug-omlonti-from-santen/2481736/Visiox Pharma announced it has entered into a definitive agreement with Santen Pharmaceutical to license glaucoma drug Omlonti (omidenepag isopropyl ophthalmic solution 0.002%). Specific financial terms of the deal were not disclosed. Omlonti was approved by th
- ASRS: Six Cases of Occlusive Retinal Vasculitis Reported After Injection of Apellis’ GA Drug Syfovrehttps://modernod.com/news/asrs-rare-cases-of-retinal-vasculitis-reported-after-injection-of-apellis-ga-drug-syfovre/2481730/Rare cases of retinal vasculitis have occurred after the first injection of Apellis Pharamceuticals’ recently approved geographic atrophy drug Syfovre (pegcetacoplan injection), according to a notification from the ASRS Research and Safety in Therapeutics (ReST) Committee. The safety concer
- Medical Consulting Group and Corcoran Consulting Group Finalize Merger Agreementhttps://modernod.com/news/medical-consulting-group-and-corcoran-consulting-group-finalize-merger-agreement/2481723/Medical Consulting Group (MCG) and Corcoran Consulting Group (CCG) have finalized their merger that was announced in April. Financial terms of the deal were not disclosed. MCG and CCG stated they believe this merger will enhance the ophthalmic community by providing
- Tenpoint Therapeutics Launches with Goal of Reversing Vision Loss Through Engineered Cell-Based Therapeuticshttps://modernod.com/news/tenpoint-therapeutics-launches-with-goal-of-reversing-vision-loss-through-engineered-cell-based-therapeutics-and-in-vivo-reprogramming/2481720/Tenpoint Therapeutics announced its launch with a $70 million Series A financing to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions. Tenpoint was established based on the work of its scientific founders from Mo
- Allotex Secures Funding for Allogeneic Presbyopia Inlayshttps://modernod.com/news/allotex-secures-funding-for-allogeneic-presbyopia-inlays/2481717/Allotex and SpA announced the first close of its $30 million Series B financing to support the further development of its technology for the treatment of refractive errors. The investment was driven by 4-year data on presbyopia and hyperopia treatments, confirming significant impro
- Cognition Therapeutics Doses First Patient in MAGNIFY Study of Oral CT1812 for GA Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-announces-dosing-of-first-patient-in-magnify-study-of-oral-ct1812-for-ga-secondary-to-dry-amd/2481714/Cognition Therapeutics announced that it has dosed the first participant in the phase 2 MAGNIFY study of CT1812, an experimental therapy being developed for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The MAGNIFY study (COG2201,
- Salvat Laboratories Initiates a Pediatric Study in Europe with SVT-15473 for the Treatment of Inflammation and Pain Following Ocular Surgeryhttps://modernod.com/news/salvat-laboratories-initiates-a-pediatric-study-in-europe-with-svt-15473-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery/2481707/Salvat Laboratories has initiated a new study with SVT-15473 clobetasol to treat inflammation and pain in patients undergoing ocular surgery. The trial will include children aged 0 to 3 years with cataracts, aiming to demonstrate the drug's safety in this population. Cataracts
- Mount Sinai Launches Center for Ophthalmic Artificial Intelligence and Human Healthhttps://modernod.com/news/mount-sinai-launches-center-for-ophthalmic-artificial-intelligence-and-human-health/2481706/The Icahn School of Medicine at Mount Sinai has launched the Center for Ophthalmic Artificial Intelligence and Human Health, the first-of-its-kind in New York and one of the first in the United States. The Center is dedicated to advancing artificial intelligence (AI) in the field of ophthalm
- Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Trial of ADX‑2191 in Patients with RPhttps://modernod.com/news/aldeyra-therapeutics-announces-improvement-from-baseline-in-retinal-function-in-phase-2-clinical-trial-of-adx2191-in-patients-with-rp/2481703/Aldeyra Therapeutics announced positive topline results from the phase 2 clinical trial of intravitreal ADX-2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa (RP). Relative to baseline, the clinical trial demonstrated statistically s
- Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Activehttps://modernod.com/news/dopavision-provides-clinical-trial-update-and-announces-all-myopiax-1-trial-sites-are-active/2481699/Dopavision announced an update on its MyopiaX-1 trial (NCT04967287). All clinical trial centers are now open and are actively screening and enrolling study participants, providing trial access to eligible children with myopia across Germany, Spain, the Netherlands, and the United Kingdom.